Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Eledon Pharmaceuticals, Inc. | d291766dex991.htm |
| EX-32.2 - EXHIBIT 32.2 - Eledon Pharmaceuticals, Inc. | d291766dex322.htm |
| EX-32.1 - EXHIBIT 32.1 - Eledon Pharmaceuticals, Inc. | d291766dex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Eledon Pharmaceuticals, Inc. | d291766dex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Eledon Pharmaceuticals, Inc. | d291766dex311.htm |
| EX-12.1 - EXHIBIT 12.1 - Eledon Pharmaceuticals, Inc. | d291766dex121.htm |
| EX-2.1 - EX-2.1 - Eledon Pharmaceuticals, Inc. | d291766dex21.htm |
| 10-K - FORM 10-K - Eledon Pharmaceuticals, Inc. | d291766d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-3 (No. 333-207359) and S-8 (Nos. 333-210058, 333-203032, and 333-200413) of Tokai Pharmaceuticals, Inc. of our report dated March 3, 2017 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 3, 2017